ClinicalTrials.gg
Active, not recruitingNCT06993116Updated Jan 28, 2026

A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of SHR-4712 Injection in Advanced Solid Tumor, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily participates in this study and signs the form.
  2. The subject is aged between 18 and 75 years old (inclusive), regardless of gender.
  3. The subject must provide tumor tissue samples for biomarker testing.
  4. The subject's performance status is 0 or 1.
  5. The expected survival time is ≥ 12 weeks.
  6. The subject has at least one that meets the requirements of v1.1.
  7. Laboratory test results confirm that the subject has sufficient functions of vital organs.
  8. Female subjects of must not be breastfeeding, have no possibility of pregnancy, and agree to comply with relevant requirements.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a history of or currently has meningeal , or has symptomatic and active central nervous system metastases.
  2. The subject has spinal cord compression that has not been radically treated by surgery and/or radiotherapy.
  3. The subject has uncontrollable tumor-related pain as judged by the investigator.
  4. The subject has clinically symptomatic moderate or severe ascites, uncontrollable pleural effusion or pericardial effusion of moderate amount or more.
  5. The subject has received systemic treatment within 14 days before the first study drug administration.
  6. The subject has active diseases or a history of autoimmune diseases with a possibility of recurrence.
  7. The subject has severe cardiovascular and cerebrovascular diseases.
  8. The subject has other uncontrolled concomitant diseases before the first drug administration.
  9. The subject has a history of severe allergic reactions to the test drug and its main formulation components.
  10. The subject has a history of immunodeficiency, including positive serological test results, and other acquired or congenital immunodeficiency diseases.
  11. The subject has had a severe infection within 4 weeks before the first drug administration.
  12. The subject has a history of active pulmonary tuberculosis infection within 1 year before enrollment as found through medical history or CT examination, or has a history of active pulmonary tuberculosis infection more than 1 year ago but has not received regular treatment.
  13. The subject has other serious physical or mental diseases, known alcohol or drug dependence, abnormal laboratory test results, and other factors that may increase the risk of participating in the study or interfere with the study results, and any other situations that the investigator deems unsuitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    SHR-4712 Group

    Drug: SHR-4712 Injection

Interventions

  • DrugSHR-4712 Injection

    SHR-4712 injection.

06

What researchers measure

Primary outcomes

  1. Dose Limited Toxicity (DLT)

    Time frame: First 21 days of treatment.

  2. Adverse Events (AEs)

    Time frame: Approximately 24 months.

Secondary outcomes

  1. Time to peak concentration (Tmax)

    Time frame: Approximately 24 months.

  2. Peak concentration (Cmax)

    Time frame: Approximately 24 months.

  3. Trough concentration (Ctrough)

    Time frame: Approximately 24 months.

  4. Area under the concentration-time curve from time zero to the last measurable time point (AUC0-t)

    Time frame: Approximately 24 months.

  5. Area under the concentration-time curve from time zero to infinity (AUC0-∞)

    Time frame: Approximately 24 months.

  6. Elimination half-life (t1/2)

    Time frame: Approximately 24 months.

  7. Apparent clearance (CL/F)

    Time frame: Approximately 24 months.

  8. Apparent volume of distribution (Vz/F)

    Time frame: Approximately 24 months.

  9. Objective response rate (ORR)

    Time frame: Approximately 24 months.

  10. Duration of objective tumor response (DoR)

    Time frame: Approximately 24 months.

  11. Disease control rate (DCR)

    Time frame: Approximately 24 months.

  12. Progression-free survival (PFS)

    Time frame: Approximately 24 months.

  13. Overall survival (OS)

    Time frame: Approximately 24 months.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 28, 2025
StartActual
Jun 9, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06993116
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Jun 9, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion